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Abstract
Recent studies showed that considerable amounts of glycosaminoglycans are released into maternal blood during normal
pregnancy and in hemolysis, elevated liver enzymes, and low platelets (HELLP) syndrome. Maternal endothelia and the
syncytiotrophoblast layer have been discussed as a possible origin of these glycocalyx components. Our study aimed to visualize
the glycocalyx on the syncytiotrophoblast by electron microscopy, to analyze its structure and composition by immunohis-
tochemistry, and to determine potential differences between healthy women and women with HELLP syndrome. For electron
microscopy, a cotyledon was fixed by perfusion of the intervillous space with a 2% lanthanum–nitrate glutaraldehyde solution
followed by immersion fixation in the same fixative. For immunohistochemistry, sections of 16 placentas (HELLP patients/healthy
women, n ¼ 8 each) were stained with monoclonal antibodies against the main glycocalyx constituents syndecan 1, hyaluronic
acid, and heparan sulfate. Semiquantitative evaluation of staining intensity focused on the apical surface of the syncytiotrophoblast
and fetal intravillous endothelia as possible localizations of a placental glycocalyx. Electron microscopy revealed a glycocalyx of
approximately 250 nm, covering the syncytiotrophoblast layer. This was found to contain large amounts of syndecan 1, but neither
hyaluronic acid nor heparan sulfate as major components. Intravillous fetal endothelium did not express any of the investigated
glycosaminoglycans. Healthy women and patients with HELLP showed no differences concerning glycocalyx composition and
thickness of the syncytiotrophoblast. The composition of the ‘‘placental’’ glycocalyx differs from the adult and fetal vascular glyco-
calyx. Obviously, the human placental syncytiotrophoblast maintains a special kind of glycocalyx at the fetomaternal interface.
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Introduction
A glycocalyx is assumed to cover the surface of all eukaryotic
cells. In recent years, pronounced scientific efforts have been
made to understand the structure and functionality especially
of the endothelial glycocalyx (EGX). The EGX is involved in
inflammatory processes and can be damaged by proinflamma-
tory mediators like tumor necrosis factor-a (TNF-a), endotox-
ins, and oxidized lipoproteins.1–5 In the vascular bed, the EGX
serves as a regulatory interface as well as an important barrier
between blood, interstitial space, and tissues. Concerning the
placenta, this role has to be ascribed to the syncytiotrophoblast
due to its epithelial nature and its direct contact with maternal
blood in the intervillous space. Although a glycocalyx structure
has not yet been visualized on the syncytiotrophoblast layer
(STL), some molecular components constituting the EGX have
already been detected in placental tissues, especially syndecan
1 and hyaluronic acid.6–8 However, the term glycocalyx has not
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been mentioned in any publication investigating this subject.
This may be due to earlier assumptions that considered the
extension of the glycocalyx to be less than 50 nm and therefore
beyond the resolution of light microscopy. However, recent
investigations have revealed that formerly the thickness of the
EGX has been severely underestimated and should be assigned
between 0.5 and 1.0 mm.9 In some investigations, it was even
shown to be up to 2 mm.10 A recent study of our group has
revealed that considerable amounts of syndecan 1 are released
into maternal blood with ongoing normal pregnancy.11 Serum
concentrations reached a median value of 10 500 ng/mL (week
38 of pregnancy), which proved to be more than 10 times
higher than that in severe sepsis.12 Elevated serum concentra-
tions of 2 further glycosaminoglycans relevant for the EGX
structure, hyaluronic acid and heparan sulfate, were only
observed in women with the syndrome of hemolysis, elevated
liver enzymes, and low platelets (HELLP syndrome). The
maternal vascular bed, as well as the placenta, has been dis-
cussed as a possible source of these EGX components, but their
exact localization remained unclear. Therefore, the current
study focused on 3 goals: 1) to visualize a glycocalyx structure
on the syncytiotrophoblast by electron microscopy and to eval-
uate whether this (putative) glycocalyx is thick enough to be
detected by light microscopy and, thus, is suitable for immuno-
histochemistry; 2) to determine by immunohistochemistry
whether the major components of the classical EGX also con-
stitute the (hypothetic) trophoblastic glycocalyx or the EGX of
the fetal intravillous vasculature; 3) to detect possible differ-
ences in the composition of the glycocalyx between healthy
women and patients with HELLP syndrome.
Methods
The research protocol was approved by the institutional
review board, and all women gave written informed consent
before enrollment. Placental tissue was sampled from 8
healthy women (normal pregnancy group [NP]) and 8 women
with verified class I or II HELLP syndrome (HELLP group
[HG]), according to the Mississippi Triple Class System. This
classification is based on platelet count nadir: class I: <50 
109/L; class II: 50  109/L to 100  109/L; class III >100 
109/L. Elevated liver enzymes (aspartate aminotransferase
[AST] or alanine aminotransferase [ALT] >70 U/L) and
hemolysis have to be present in any case.13,14 Patients with
preexisting (prior to pregnancy) or gestational diabetes melli-
tus, preexisting arterial hypertension, vascular diseases,
chronic or acute infections, or undergoing glucocorticoid
therapy were excluded from the study as these conditions are
known to impact the glycocalyx. None of the patients had
been given heparin or heparin-like drugs.
Electron Microscopy
Electron microscopy was performed in a term placenta derived
from a healthy woman.
Tissue preparation, fixation, and staining. For electron microscopy,
a lanthanum–nitrate glutaraldehyde fixative was applied. A pre-
condition for a successful lanthanum fixation is a constant flow
of the fixative along glycocalyx-bearing cell surfaces for at least
30 seconds. This was achieved by the following procedure:
immediately after delivery, the placenta was turned onto the fetal
side. Two custom-made semicircular surgical clamps (diameter
5 cm) were positioned around a group of cotyledons situated at
the placental margin. Thus, the encircled area extended from the
placental margin about 5 cm in the direction of the umbilical
insertion point, leaving a small section (about 1 cm) at the outer
rim of the enclosed cotyledons for manipulations. Here a deep
horizontal cut, about 1 cm wide, was made with a scalpel. Next,
a needle attached to a 20-mL syringe was inserted vertically into
the middle of the enclosed section and pushed forward until
blood could be aspirated. Afterward, 40 mL of NaCl 0.9% solu-
tion were slowly injected into the enclosed cotyledons, washing
out the intervillous blood via the preformed marginal cut. This
procedure was followed by a slow injection of 20 mL of a freshly
prepared solution of the lanthanum fixative, the composition of
which is described in detail elsewhere, into the intervillous space
to perfuse the syncytiotrophoblast surfaces.9 Again, the overflow
left the enclosed section via the marginal cut. After 5 minutes of
latency to stabilize fixation, the enclosed section was removed
from the placenta by sharp dissection along the clamps. Subse-
quently a horizontal dissection through the former enclosed
cotyledons was made to reveal the fixed STLs and 4 small dices
(each 1 mm3) were obtained (1 perimarginal, 2middle of the
section, and 1 as near as possible to the middle of the placenta).
Further fixation, washing, and contrast enhancement proceeded
according to a protocol described by Chappell, in 2009.9 After
embedding in araldite and sectioning, electron microscopy (Phi-
lips CM, Aachen, Germany) was performed as previously
described.15
Immunohistochemistry
Tissue preparation, fixation, and staining. Immediately after birth
of the placenta, small lamellar tissue blocks including the fetal
membranes were obtained by sharp dissection from the inser-
tion point of the umbilical cord to the peripheral margin. After-
ward, out of these stripes, 3 pairs of small blocks (about 9 mm3)
were excised near cord insertion, middle, and placental margin,
respectively. Materials were obtained within 5 minutes after
placental delivery and fixed in 4% formalin for 24 hours. Par-
affin sections (5 mm) of every placenta were immunohisto-
chemically stained with monoclonal antibodies against
syndecan 1 (R&D Systems Inc, Minneapolis, Minnesota), hya-
luronic acid (AbD Serotec MorphoSys GmbH, Germany), or
heparan sulfate (Seikagaku Corp, Japan). Sections were incu-
bated with 3% H2O2 for 30 minutes to inhibit endogenous per-
oxidase activity. Nonspecific antibody binding was blocked
with 3% rabbit-0-serum or goat-0-serum (heparan sulfate) in
phosphate-buffered saline for 30 minutes. The primary antibo-
dies were diluted and pretreated with biotinylated secondary
antibodies, corresponding to the initial blocking procedure.
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Streptavidin–peroxidase conjugates (Vectastain-Kit, Vector
Inc, Burlingame, California) were used to transfer peroxidase
activity to the sites of antibody binding. Controls were treated
identically, but the primary antibody was replaced with buffer
(Figure 5A-F). Visualization was routinely achieved by perox-
idase detection with diaminobenzidine as chromogen. Finally,
all preparations were counterstained with hematoxylin.
Semiquantitative comparison of staining intensity. Preparations
were examined by light microscopy using a 40-fold magnifica-
tion. They were subdivided into 12 to 20 randomly selected,
noncoherent fields of view, depending on the surface area of
each section. Each field of view was digitally photographed.
Afterward, the digital photographs were overlaid by a black
grid subdividing them into 48 fields with the help of graphic
software (ImageJ 1.44p; Wayne Rasband, National Institute
of Health, USA). For each field, the intensity of staining was
evaluated by 2 blinded investigators, using a modified version
of the ‘‘h-score,’’ with 0¼ no staining, 1¼weak, 2¼mild, and
3¼ strong staining.16 Staining was only regarded as positive in
case it occurred either on the apical surface of the STL or on the
apical surface of the fetal intravillous endothelium. If the stain-
ing intensity varied within one field of the grid, the most inten-
sively colored parts of the syncytiotrophoblast were evaluated
and the highest score was noted. Thus, 29 840 fields were eval-
uated in total.
Statistics. Mean, standard deviation of the mean, median, and
25th/75th percentile were calculated for demographic and
experimental data. To test normality, the Shapiro-Wilks test
was applied. Because most of the data were not normally dis-
tributed, they are presented as median + 25th/75th percentile.
For intergroup comparisons concerning the intensity of immu-
nohistochemical staining the Mann-Whitney Rank-Sum test
was applied. For all determinations, a type I error protection
of P < .05 was considered significant. Statistical analysis was
performed using Sigma Stat Software version 3.1 (RockWare
Inc, Golden, Colorado).
Results
Demographic and Clinical Data
The demographic data of the women enrolled and of their neo-
nates are presented in Table 1. Except for gestational age at
delivery and the body weight of the neonates, there were no sig-
nificant differences between NP and HG.
Electron Microscopy (Healthy, Term Placenta)
A glycocalyx was visualized ex vivo on the surface of the syn-
cytiotrophoblast of all analyzed fields. Although its structure
was not preserved over the complete STL, large areas (about
50% of the syncytiotrophoblast surface) showed components
of the glycocalyx structure in 2 areas, namely (i) at the apical
surface of the syncytiotrophoblast in bush-like dense arrange-
ments and (ii) intracellularly, predominantly with bush-like
structures projecting into vacuoles in the intra-STL. No differ-
ences were observed between samples taken from different
locations of the placenta (see methods section), either with
regard to appearance or structure of the glycocalyx or with
regard to the degree of damage and preservation, respectively.
The intrasyncytiotrophoblastic zone reached a thickness
between 600 and 1000 nm, the apical zone between 150 and
300 nm (Figures 1 and 2). Both zones together proved to extend
between 900 and 1300 nm in diameter.
The filamental zone only partially resembled the structure of
the glycocalyx discovered on human umbilical venous
endothelium.9,10 Filaments covering the syncytiotrophoblast
surface were virtually grouped in bush-like entities, their tips
clearly directed to the intervillous space. However, unlike the
EGX, an apical cell membrane as a base for membrane-
bound syndecans and transmembrane glypicans was barely dif-
ferentiated. In the intrasyncytiotrophoblastic zone, numerous
vacuoles were observed. These vacuoles were obviously filled
with glycocalyx filaments. In this zone, discrimination between
syncytiotrophoblast cytoplasm and glycocalyx material was
difficult; the typical microvilli were hardly circumscribable.
In other fields of view, wide areas of the syncytiotrophoblast
surface were covered by a broad margin (about 2-4 mm) of dis-
rupted glycocalyx fragments and/or cellular debris, respec-
tively (Figure 3).
Immunohistochemistry
Microscopical analyses focused on the apical surface of the
STL and on the endothelium of intravillous fetal blood vessels.
Positive reactions of other placental structures are not
described and did not contribute to the findings concerning the
intensity of immunohistochemical staining. The distribution of
intensity score ratings is presented in Table 2.
Figure 1. Electron microscopy of the apical surface of the syncytio-
trophoblast layer after lanthanum fixation. Term placenta, undisturbed
pregnancy. Original magnification: 30 000-fold. V indicates vacuoles
covered with glycocalyx filaments; GX, glycocalyx.
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Syndecan 1. Syndecan 1 was strongly expressed on the apical
surfaces of the STL of all villi of normal, term placentas as well
as of placentas gained from patients with HELLP (Figure 4A
and D). More than 80% of the fields evaluated showed a score
3 reaction product (median modified H-score ¼ 2.8 for both
groups). Significant differences in terms of staining intensity
between the HG and the NP could not be observed. The fetal
endothelium remained completely unstained in all fields of
view evaluated.
Hyaluronic acid. Compared to syndecan 1, the expression of
hyaluronic acid on the apical surface of the syncytiotrophoblast
was substantially less intense (median modified H-score ¼ 0.6
for both groups). There were more negative staining reactions
in the HG (HG 50.0% vs NP 39.3%), but definite statistical
differences in terms of staining scores between the groups could
not be noticed. In contrast to syndecan 1, hyaluronic acid some-
times could also be localized in the more basal parts of the syn-
cytiotrophoblast, in the cytotrophoblast, and in basal membranes
of the fetal endothelium (not shown). The luminal surface of the
fetal endothelial layer did not demonstrate any positive reaction
product (Figure 4B and E).
Heparan sulfate. There was hardly any positive expression of
heparan sulfate on the STL in the investigated fields of
view. A score 1 reaction product could be identified on the
apical surface in less than 5% of the sections (median
modified H-score ¼ 0.0 for both groups). The endothelium
of intravillous blood vessels remained unstained as well
(Figure 4C and F).
Table 1. Demographic and Clinical Data of the Women Enrolled and Their Neonates.a
Groups (n) HG (n ¼ 8) NP (n ¼ 8) P values, HG vs NP
Women
Age, years 35 (34/36) 32 (31/35) .15
Height, cm 165 (163/177) 168 (164/171) .68
Body weight prior to pregnancy, kg 65 (60/71) 67 (65/74) .42
Body weight after delivery, kg 72 (71/82) 74 (69/81) .92
Gestational age at delivery, weeks 33.0 (31.2/35.5) 39.0 (37.0/39.5) <.001
Cesarean section/spontaneous delivery, n 8/0 2/6 na
Neonates
Body weight, g 1990 (1407/2512) 2935 (2672/3236) .03
APGAR-score 1/5/10 minutes postpartum, points 8/10/10 9/9/10 .1/.2/.3
Arterial umbilical cord pH 7.31 (7.29/7.33) 7.33 (7.28/7.36) .7
Arterial umbilical cord BE 1.0 (1.6/0.1) 2.0 (3.9/0.4) .5
Abbreviations: na, not applicable; HG, HELLP group; NP, normal pregnancy group; HELLP syndrome, hemolysis, elevated liver enzymes, and low platelets
syndrome.
a Data are given as median with 25th/75th percentile in parenthesis.
Figure 2. Electron microscopy of the apical surface of the syncytiotro-
phoblast layer after lanthanum fixation. Term placenta, undisturbed
pregnancy. Original magnification: 49 000-fold. GX, indicates glycocalyx.
Figure 3. Human term placenta, luminal surface of the syncytiotro-
phoblast layer after lanthanum fixation. The syncytiotrophoblast layer
is covered by disrupted glycocalyx fragments and/or cellular debris.
Due to the perfusion technique, the glycocalyx of the fetal endothe-
lium could not be imaged. Original magnification: 3000-fold.
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Discussion
The existence of a glycocalyx structure on the apical surface of
the syncytiotrophoblast is evident, but, until now, neither has it
been verified via electron microscopy nor has its molecular
composition been clarified via immunohistochemistry. In the
current study, a glycocalyx could be identified on the
Figure 4. A-F, Immunohistochemical localizations of glycocalyx components on the syncytiotrophoblast layer. A-C, Normal term placenta, 39
weeks of gestation. A, Syndecan 1. Stainings presented themselves either as deeply brown to nearly black membranes (arrow 1; grade 3 H-score)
or as slightly loosened layers (arrow 2). Small, magnified sections of another image of the same patient were integrated into this figure to give a
more detailed view on these 2 types of staining reactions. The endothelium of fetal vessels remained completely unstained (arrow 3). Original
magnifications: main picture 40-fold; magnified sections 80-fold. B, Hyaluronic acid. Grade 2 H-score. The endothelium of fetal vessels remained
completely unstained. Original magnification: 40-fold. C, Heparan sulfate. The apical surface of the syncytiotrophoblast and the endothelium of
fetal vessels remained completely unstained (grade 0 H-score). Original magnification: 20-fold. D-F, The placenta of patients with HELLP syn-
drome, 33 weeks of gestation. D, Syndecan 1. The black membranes and the slightly loosened layers (corresponding to Figure 4A) can also be
identified. Original magnification: 40-fold. E, Hyaluronic acid. Grade 2 H-score. Original magnification: 40-fold. F, Heparan sulfate. Some positive
staining reactions are detectable near the basal membranes of the syncytiotrophoblast (arrow 1) and in the cytotrophoblast. The apical surface
of the syncytiotrophoblast and the endothelium of fetal vessels remained unstained (grade 0 H-score). Original magnification: 20-fold.
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syncytiotrophoblast surface by applying a new method of per-
fusion fixation for placental electron microscopy. In addition,
with up to 1100 nm in size this glycocalyx was found to be suit-
able for light microscopy. Despite these basic observations,
some additional ultrastructural features of the syncytiotropho-
blast’s glycocalyx could be described. However, these findings
have to be carefully interpreted due to the fact that only one
placenta was investigated by electron microscopy. Electron
microscopy as well as immunohistochemical staining suggests
that the composition of the ‘‘placental’’ glycocalyx differs from
the EGX of adult humans.
Concerning its ultrastructure, especially the ‘‘nonexistence’’
of a visible apical cell membrane contrasts to that of EGX.
Although the number and length of the placental microvilli are
reduced with ongoing pregnancy, it is likely that the nonlinear
surface pattern of the syncytiotrophoblast prevents the forma-
tion of a ‘‘straight line’’ continuous glycocalyx and, thus,
conceals the apical cell membrane of the STL.17
Various investigators have tried to evaluate the thickness of
the EGX.4,15,18–20 Today, the extension of the EGX is thought
to be up to 0.5 mm, some investigators even measured 2 mm
by confocal laser scanning microscopy, depending on the loca-
tion within the vascular system.10,21 With a thickness of about
250 nm, the glycocalyx covering the STL in the current study
seems to be half the size of the EGX of major blood vessels and,
at first sight, at the limit of visibility when investigated via light
microscopy. However, in contrast to vasculature, placental gly-
cocalyx filaments were not only localized along the STL’s sur-
face, but a dense ‘‘inner zone,’’ corresponding to numerous
intrasyncytiotrophoblastic vacuoles (or perhaps invaginations),
could also be identified (extension about 1100 nm), in which
glycocalyx filaments seemed to be embedded while ‘‘carpeting’’
the inner surface of these vacuoles. Vacuoles or vesicles in
between the syncytiotrophoblast stroma have been described
by various authors; their functions have not yet been fully under-
stood.17,22 Haigh et al thought it is possible that some of the api-
cal vacuoles discharge their contents into the intervillous space
and afterward function as a type of residual membranous body.23
Despite the fact that the synthesis of the glycocalyx is not well
understood, one can speculate that glycocalyx-covered vacuoles
can migrate to the STL’s surface and may be integrated into its
apical membrane with its glycocalyx-covered surface directed to
the intervillous space.
The fact that glycocalyx filaments—at least in the current
experiment—are localized on the surface as well as in a
1 mm broad zone of the cytoplasm of the syncytiotrophoblast,
is in accordance with the immunohistochemical findings; syn-
decan 1 can be detected not only on the apical surface (where it
displayed the highest staining intensity), but also in the syncy-
tiotrophoblast plasma in the current study, as well as in previ-
ous investigations (Figure 4A and D).6,7 Besides large areas
covered by an intact glycocalyx, in the current study, other
parts of the STL displayed a surface clad only by disrupted gly-
cocalyx fragments and/or cellular debris. Due to the limitations
of ultrastructural imaging, the current investigation is not
appropriate to decide whether this is physiological and only
reflects an enormous cellular turnover (what would correspond
to high maternal serum levels of glycocalyx components11), or
has to be interpreted as an unnatural damage due to the begin-
ning of tissue hypoxia after delivery. The lanthanum-perfusion
technique applied here perfused only the intervillous space.
Thus the EGX presumably lining fetal vessels escapes repre-
sentation from electron microscopy. However, the existence
of a fetal EGX has already been confirmed by an ultrastructural
investigation performed by Eaton et al in 1993.24 With immu-
nohistochemistry both the fetal (endothelial) and the maternal
(syncytial) side of the feto-maternal interface, can be analyzed.
Indeed, syndecan 1, heparan sulfate, and hyaluronic acid have
already been detected in a variety of localizations in the human
placenta.6–8,25–29 Unfortunately, the results of previous studies
vary both for the local expression and for staining intensity of
these components in placental tissues. Their expression has also
been investigated in the context of different pregnancy disorders,
but quantitative comparisons of immunohistochemical staining
intensity are generally rare, and patients with HELLP syndrome
have not yet been investigated.6,29 The current study adds new
aspects to the ongoing discussion on glycosaminoglycans in pla-
cental compartments by focusing on the glycocalyx of the
placenta’s epithelial structures: the syncytiotrophoblast and the
endothelium of the fetal intravillous vasculature.
Concerning syndecan 1, data provided by the current study
confirm and amend the results of Crescimanno and coworkers
who noticed a strong expression along the apical plasma
membrane of the syncytiotrophoblast.6 Comparative investi-
gations on the staining intensity of syndecan 1 on the STL’s
surfaces in patients with HELLP patients are not available,
but Jokimaa et al reported a reduced syndecan 1 expression
on the chorionic villi in severe preeclampsia.29 This discre-
pancy to the current investigation is difficult to interpret,
because Jokimaa et al did not exclusively refer to the STL.







Score 0, % .0 (0.0/0.6) 50.0 (22.9/77.5) 100 (86.1/100)
Score 1, % 0.0 (0.0/2.9) 26.3 (18.4/42.1) 0.0 (0.0/13.9)
Score 2, % 10.0 (4.7/18.1) 7.9 (0.0/27.6) 0.0 (0.0/0.0)
Score 3, % 86.7 (76.3/94.7) 0 (0/0) 0.0 (0.0/0.0)
Median H-
score
2.8 (2.7/2.9) 0.6 (0.2/1.0) 0.0 (0.0/0.1)
NP
Score 0, % 0.0 (0.0/3.4) 39.3 (13.2/72.7) 97.7 (85.1/100)
Score 1, % 0.0 (0.0/10.0) 29.0 (16.0/45.6) 2.3 (0.0/14.5)
Score 2, % 12.1 (3.8/20.9) 10.3 (0.0/30.9) 0.0 (0.0/0.0)
Score 3, % 83.0 (62.6/95.1) 0.0 (0.0/2.6) 0.0 (0.0/0.0)
Median H-
score
2.8 (2.4/2.9) 0.6 (0.3/1.3) 0.0 (0.0/0.2)
Abbreviations: HG, HELLP group; NP, normal pregnancy group; HELLP
syndrome, hemolysis, elevated liver enzymes, and low platelets syndrome.
a Data are shown as median (25th/75th percentile).
b Significant differences between groups could not be observed, P > .05 for all
comparisons.
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In addition, it is still unclear whether study results obtained
from women with preeclampsia are transferable to patients
with HELLP. Nevertheless, the equal staining intensities of
syndecan 1 on the STL in NP and HG speak in favor of the
assumption that the large amount of syndecan 1 measured in
the blood of patients with HELLP, which exceeds the elevated
levels measured in healthy women, might at least partially
derive from the maternal vasculature.11
With respect to intravillous fetal endothelium, we did not
notice any positive reaction products for syndecan 1. This
again is in accordance with the results provided by Cresci-
manno et al who also noted the absence of syndecan 1 but
found syndecan 2 in the walls of fetal vessels, particularly
in the endothelium in the 9th week of gestation.6 This is
remarkable, because Chappell et al were able to detect syn-
decan 1 in the umbilical veins and arteries of term placen-
tas.9 It is unclear whether syndecan 1 expression patterns
can change with ongoing pregnancy (what seems possible
according to Crescimanno’s studies), or whether the compo-
sition of the EGX of chorionic endothelia principally differs
from the EGX of fetal umbilical vessels. The results con-
cerning hyaluronic acid and heparan sulfate provided by
the current investigation do speak in favor of the latter
possibility.
Figure 5. A-F, Negative controls. A-C, Normal term placenta, 39 weeks of gestation. A, Syndecan 1. B, Hyaluronic acid. C, Heparan sulfate. D-F,
The placenta of patients with HELLP syndrome, 32 weeks of gestation. D, Syndecan 1. E, Hyaluronic acid. F, Heparan sulfate. Original magnifications
5A-F: 40-fold.
Hofmann-Kiefer et al 1243
Regarding hyaluronic acid, weak to moderate staining was
detectable on the apical surface of the STL in 50% (NP) and
39% (HG) of the sections investigated. In 2010, Gao et al
reported that enzymatic degradation of hyaluronic acid reduces
the thickness of the EGX by 26%, indicating that hyaluronic
acid is not the predominant glycosaminoglycan in the EGX.30
Although certainly not directly comparable, these findings do
correspond to our results concerning the weak to moderate
staining intensity of hyaluronic acid on the STL we observed.
Surprisingly the fetal endothelia displayed no staining. There
is one comparable study performed by Matejevic et al who
observed hyaluronic acid in the fetal vessel walls (tunica
intima, media, and adventitia), but the authors unfortunately
did not refer to the endothelium.8
For heparan sulfate, the third major component of the EGX
examined in the current study, only minimal traces of reaction
products could be detected on the STL and none on fetal endothe-
lia. Again no relevant difference existed between patients with
HELLP and healthy women. Older studies are not completely
in accordance with these results. For example, Wasserman et al
observed that heparan sulfate was associated with intravillous
blood vessels and the syncytiotrophoblast but did not provide data
concerning the intensity and exact localization of their findings.
Placental tissue obtained from patients with pregnancy disorders
was not examined in Wasserman’s investigation.31
The current study focused on healthy women and patients
with HELLP syndrome and did not include women with pree-
clampsia. In addition, we did not investigate placentas gathered
from women whose prematurity (see Table 1) was not caused by
a HELLP syndrome. This might be considered as a limitation.
However, although preeclampsia is well defined by international
protocols, these protocols usually leave space for a variety of
clinical manifestations and are partially independent from the
severity of the disease.32,33 Integrating women with preeclamp-
sia probably would have led to an inhomogeneous study popula-
tion and, thus, complicated the interpretation of results. In
contrast, HELLP syndrome is unmistakably defined by a typical
set of laboratory values, the women concerned definitely display
severe clinical symptoms and the disease is clearly associated
with inflammation.14,34 In terms of prematurity, inflammation
is supposed to account for the bigger part of preterm deliv-
eries.35–39 Even in cases without obvious inflammatory back-
ground (eg, cervix insufficiency), inflammation is considered
to be a conductive factor.38 However, the most important causes
of glycocalyx destruction are inflammation and ischemia.1,12,40
Thus, until the origin of prematurity is completely understood,
‘‘normal’’ (non-HELLP) preterm placentas would have led to
an unpredictable integration of factors influencing the glycoca-
lyx’s structure and integrity; perhaps preterm delivery per se,
surely inflammation and probably ischemia. This again would
have hindered a reasonable interpretation of study results.
Accordingly, it seemed advantageous to include only women
with HELLP syndrome in the current study and, as a conse-
quence, to compare 2 well-defined groups of pregnancies with
and without an inflammatory background, even if this led to rel-
atively small study groups.
Conclusion
Summarizing the results of immunohistochemistry and elec-
tron microscopy, one can state that the glycocalyx detected
on the STL obviously deviates from the EGX with regard to the
composition of its major components and its structure. Espe-
cially the scarcity of heparan sulfate on the apical surface of the
STL emphasizes the constitutional differences to the adult
EGX and, on the other hand, supports the hypothesis that ele-
vated heparan sulfate and hyaluronic acid serum concentrations
in women with HELLP syndrome do not derive from the pla-
centa, but rather from the maternal vasculature (or other ori-
gins). HELLP syndrome, as an inflammatory disorder, did
not influence the results of semiquantitative immunohisto-
chemistry. Concerning the EGX of fetal vessels, the findings
of the current study only partially correspond to previous inves-
tigations. Further research is required to exactly define the
composition and structure of this side of the fetomaternal
barrier.
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